

**PHS PUBLIC ACCESS**

Author manuscript

*Nat Neurosci.* Author manuscript; available in PMC 2018 January 17.

Published in final edited form as:

*Nat Neurosci.* 2017 September ; 20(9): 1217–1224. doi:10.1038/nn.4598.**Rates, Distribution, and Implications of Post-zygotic Mosaic Mutations in Autism Spectrum Disorder**

**Elaine T. Lim**<sup>1,2,3,4,\*</sup>, **Mohammed Uddin**<sup>5</sup>, **Silvia De Rubeis**<sup>6,7</sup>, **Yingleong Chan**<sup>2,3,4</sup>, **Anne S. Kamumbu**<sup>1,2,3</sup>, **Xiaochang Zhang**<sup>1,2,3</sup>, **Alissa D'Gama**<sup>1,2,3</sup>, **Sonia N. Kim**<sup>1,2,3</sup>, **Robert Sean Hill**<sup>1,2,3</sup>, **Arthur P. Goldberg**<sup>6,7</sup>, **Christopher Poultney**<sup>6,7</sup>, **Nancy J. Minshew**<sup>8</sup>, **Itaru Kushima**<sup>9</sup>, **Branko Aleksic**<sup>9</sup>, **Norio Ozaki**<sup>9</sup>, **Mara Parellada**<sup>10</sup>, **Celso Arango**<sup>10</sup>, **Maria J. Penzol**<sup>11</sup>, **Angel Carracedo**<sup>12,13,14</sup>, **Alexander Kolevzon**<sup>15,16,17,18,19</sup>, **Christina M. Hultman**<sup>20</sup>, **Lauren A. Weiss**<sup>21</sup>, **Menachem Fromer**<sup>6,7,22</sup>, **Andreas G. Chiocchetti**<sup>23</sup>, **Christine M. Freitag**<sup>23</sup>, **Autism Sequencing Consortium**<sup>30</sup>, **George M. Church**<sup>2,3</sup>, **Stephen W. Scherer**<sup>24,25,26,27</sup>, **Joseph D. Buxbaum**<sup>6,7,28,29</sup>, and **Christopher A. Walsh**<sup>1,2,3,\*</sup>

<sup>1</sup>Division of Genetics and Genomics, Manton Center for Orphan Disease Research and Howard Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115, USA

<sup>2</sup>Departments of Genetics, Pediatrics and Neurology, Harvard Medical School, Boston, MA 02115, USA

<sup>3</sup>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02138, USA

<sup>4</sup>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA

<sup>5</sup>Mohammed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, UAE

<sup>6</sup>Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

<sup>7</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

<sup>8</sup>Department of Psychiatry, Center For Excellence in Autism Research, University of Pittsburgh, Pittsburgh, PA, USA

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Correspondence to: C.A.W. (Christopher.Walsh@childrens.harvard.edu) or E.T.L. (elimtt@gmail.com).

<sup>30</sup>A list of members and affiliations appears in Supplementary Note.

**Accession codes:** The raw WES data has been in part deposited into NDAR (#2337), and we will ensure that the new data will be deposited upon publication.

**Competing Financial Interests:** Drs. Scherer and Uddin and the Hospital for Sick Children hold intellectual property used in this analysis, which is also licensed by Lineagen, Inc. Dr Parellada has received educational honoraria from Otsuka, research grants from Fundación Alicia Koplowitz and Mutua Madrileña and travel grants from Otsuka and Janssen. Dr Arango has been a consultant to or has received honoraria or grants from Abbot, Amgen, AstraZeneca, Bristol-Myers-Squibb, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Takeda, and Schering-Plough.

- <sup>9</sup>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
- <sup>10</sup>Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, CIBERSAM, Madrid 28007, Spain
- <sup>11</sup>Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, IISGM, CIBERSAM, Madrid 28007, Spain
- <sup>12</sup>Grupo de Medicina Xenomica, Universidade de Santiago de Compostela, Centro Nacional de Genotipado-Plataforma de Recursos Biomoleculares y Bioinformaticos-Instituto de Salud Carlos III (CeGen-PRB2-ISCI), Santiago de Compostela 15782, Spain
- <sup>13</sup>Grupo de Medicina Xenomica, CIBERER, Fundacion Publica Galega de Medicina Xenomica-SERGAS, Santiago de Compostela 15782, Spain
- <sup>14</sup>Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
- <sup>15</sup>Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- <sup>16</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- <sup>17</sup>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- <sup>18</sup>The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- <sup>19</sup>Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- <sup>20</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- <sup>21</sup>Department of Psychiatry and Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA
- <sup>22</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA
- <sup>23</sup>Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Autism Research and Intervention Center of Excellence, University Hospital Frankfurt, Goethe University, Frankfurt am Main 60528, Germany
- <sup>24</sup>The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Ontario, Canada
- <sup>25</sup>Program in Genetics and Genome Biology (GGB), The Hospital for Sick Children, Toronto, Ontario, Canada
- <sup>26</sup>Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
- <sup>27</sup>McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada
- <sup>28</sup>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

<sup>29</sup>The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

## Abstract

We systematically analyzed post-zygotic mutations (PZMs) in whole-exome sequences from the largest collection of trios (5,947) with autism spectrum disorder (ASD) available, including 282 unpublished trios, and performed re-sequencing using multiple independent technologies. We identified 7.5% of *de novo* mutations as PZMs, with 83.3% of these PZMs not discovered in previous studies. Damaging, non-synonymous PZMs within critical exons of prenatally-expressed genes were more common in ASD probands than controls ( $P < 1 \times 10^{-6}$ ), and genes carrying these PZMs were enriched for expression in the amygdala ( $P = 5.4 \times 10^{-3}$ ). Two genes (*KLF16* and *MSANTD2*) were significantly enriched for PZMs genome-wide, and other PZMs involved genes (*SCN2A*, *HNRNPU*, *SMARCA4*) known to cause ASD or other neurodevelopmental disorders. PZMs constitute a significant proportion of *de novo* mutations and contribute importantly to ASD risk.

## Introduction

Autism spectrum disorder (ASD) is a complex disorder with genetic and clinical heterogeneity. Beyond common variation<sup>1</sup>, previous studies focusing on germline mutations have demonstrated a significant contribution from *de novo* copy number variants (CNVs)<sup>2,3</sup>, and more recent whole-exome sequencing (WES) analyses have highlighted the role of *de novo* point mutations<sup>4,5</sup>. Although the number of exonic *de novo* mutations is similar between affected and unaffected individuals ( $\approx 1$  *de novo* point mutation per exome), ASD probands harbor an excess of deleterious and loss-of-function (LoF) *de novo* mutations in exons compared to their unaffected siblings<sup>4,5</sup>. Collectively, 4-7% of probands have a *de novo* CNV and  $\sim 7\%$  of probands have a *de novo* point mutation that confers risk to ASD<sup>2</sup>. Additionally, WES studies have uncovered risk to ASD from rare autosomal recessive (3%) and X-linked variants (2%)<sup>6,7</sup>. However, a large portion of ASD risk cannot be explained by germline *de novo*, recessive and X-linked variants, and this warrants investigation of other genetic contributions to ASD risk.

Post-zygotic mutations (PZMs) result in distinct cell populations within the same individual, which can contribute to varying disease manifestations. These mutations are typically not transmitted to the offspring and it has been hypothesized that PZMs account for a significant proportion of genetic risk in sporadic disorders. There is increasing recent evidence that PZMs can contribute to brain malformations and epilepsy<sup>8,9</sup>, and that a fraction of clinically relevant PZMs can be detected in blood of affected individuals<sup>8,10</sup>. The role of PZMs in ASD risk is unknown and we therefore explored the contribution of this type of variation to ASD. PZMs are efficiently detected by candidate gene sequencing panels, given their deep sequencing coverage. However, PZMs present in greater than 25-30% of cells (or 15% alternate allele fraction (AAF)) can be detected with reasonable sensitivity using WES<sup>8</sup>. We re-called WES data from 5,947 trios, adding 282 newly sequenced trios, from the Autism Sequencing Consortium and Simons Simplex Collection, and using a custom pipeline, we

resequenced PZMs detected from WES data using 3 resequencing technologies, providing a systematic evaluation of PZM's contribution to ASD risk.

## Results

### Excess of *de novo* mutations with low AAFs

We analyzed *de novo* mutations in WES data from 5,947 families, which included 4,032 ASD trios and 1,918 quads that also have unaffected siblings (Supplementary Tables 1-3)<sup>4,5</sup>. The vast majority of samples (96%) were derived from whole blood DNA, and a negligible fraction from lymphoblastoid cells (3%) and primary saliva (1%). We included all samples derived from various tissue types, but removed outlier samples with a large number of *de novo* or mosaic mutations from our analyses (see Methods). We increased specificity for likely pathogenic mutations by filtering out variants that are present in control exomes, resulting in modestly lower rates of *de novo* mutations than previously called (4,846 in total). Of these, a substantial portion (23%) showed low AAFs of  $\leq 40\%$  (Fig. 1A). The modal AAF was  $\approx 50\%$ , which is consistent with the expected AAF for a germline heterozygous mutation. We observed a 1.4-fold excess of mutations in the 40%-50% AAF category compared to the 50%-60% AAF category, suggesting a modest bias towards mutations with lower AAFs, possibly due to amplification, capture or sequencing biases for the alternate alleles. In contrast, we observed a robust (4.1-fold) excess of mutations with AAF  $\leq 40\%$  (23.7% of all *de novo* mutations), compared to those with AAF  $\geq 60\%$  (5.8% of all *de novo* mutations), suggesting that a significant proportion of mutations with AAF  $\leq 40\%$  arose from a biological mechanism rather than a technical bias. In addition, there is an excess of *de novo* point mutations compared to inherited variants in the AAF  $\leq 40\%$  category (odds ratio OR = 1.67), that was not seen in the AAF  $\geq 60\%$  category (OR = 0.82). This suggests that a significant portion of *de novo* mutations is likely to have arisen post-zygotically rather than in the parental gametes.

### Detection of PZMs from WES and secondary resequencing

Given our initial observations that some *de novo* mutations might be PZMs, we developed a pipeline to quantitatively categorize PZMs with high or low confidence in our cohort of 5,947 ASD families (see Methods). Of 4,846 total *de novo* mutations (which we define as Group A, Fig. 1B), 1,113 were candidate PZMs (23%, Group B), defined as having an AAF that was  $\leq 80\%$  of the modal AAFs, which ranged from 40-50%. Of these Group B mutations, 468 were interpreted as high-confidence PZMs (9.7%, Group C) because they showed statistically significant deviation from the modal AAFs.

We compared the 4,846 *de novo* mutations in Group A from our study with previous studies reporting these datasets<sup>4,5</sup>, and found that 1,297 of the *de novo* mutations (26.8%) we identified had not been previously reported in ASD. We enriched for *de novo* mutations that are most likely to be pathogenic and to have a large effect in ASD, by filtering away *de novo* mutations found in control individuals. As such, our reported rate of *de novo* mutations is conservative – on average, less than 1 *de novo* mutation per exome. However, we also recalled the exomes jointly using the latest GATK variant calling pipelines and best practices. This likely accounts for improved detection of previously unreported mutations.

To experimentally test the candidate PZMs, we applied independent resequencing methods in three phases. In Phase 1, we resequenced 50 mutations, based on sample availability, across the three groups (Table 1) using three independent technologies - pyrosequencing, subcloning with Sanger colony sequencing (CloneSeq), and targeted PCR followed by MiSeq resequencing (Supplementary Table 4), to test whether these mutations deviated from the expected AAF of 50%, and to compare these technologies. We found that 84.8-93.3% of the Group C mutations, predicted to be high-confidence PZMs, were indeed likely to arise post-zygotically with confirmed AAFs 40% (Table 1). Of the less stringent candidate PZMs (in Group B but not in C), 25-38% were confirmed as post-zygotic with AAFs 40%. In Phase 2, we resequenced another 181 mutations from all groups using targeted PCR and MiSeq, as well as pyrosequencing, and replicated the rates observed in Phase 1: 84.8-85.2% of high-confidence PZMs (Group C) and 13.5-25.6% of less stringent PZMs (Group B) showed AAFs 40%. A small percentage (8.3%) of predicted germline *de novo* mutations (gDNMs) found only in Group A (and not identified as also being in Groups B or C) also showed AAFs 40%. In Phase 3, we resequenced a larger number of 325 mutations using targeted PCR and MiSeq with DNA derived from blood samples, and found that 97% of high-confidence PZMs, 17.6% of less stringent PZMs, and 2.8% of predicted gDNMs have AAFs 40%.

The Pearson's correlations between AAFs detected from WES compared to the 3 resequencing technologies ranged from 0.52 to 0.58, apparently reflecting mainly the relatively low coverage, and hence imprecise AAFs from WES. In contrast, AAFs determined using CloneSeq and targeted PCR with MiSeq were more highly correlated with one another, at 0.85 (Fig. 1C). Although CloneSeq is an excellent standard for measuring the AAF of PZMs, it is low-throughput and expensive. Our data suggest that targeted PCR with MiSeq is an acceptable alternative that is higher throughput. AAFs determined with pyrosequencing showed lower correlation with CloneSeq, at 0.63. In particular, pyrosequencing did not correlate well with CloneSeq at lower AAFs (Fig. 1C), e.g., AAFs 40% (Pearson's correlation = 0.64), unlike targeted PCR with MiSeq (Pearson's correlation = 0.92), suggesting a larger variation in detecting lower AAFs using pyrosequencing.

We also tested 82 *de novo* mutations using Sanger sequencing, and found that 73 of them (or 89%) are confirmed as genuine *de novo* mutations, i.e., the mutations were not present at a detectable AAF in the parents' DNA samples. We confirmed this initial result using targeted PCR with MiSeq for another 327 *de novo* mutations and found that 84.1% of the PZMs from Group C were confirmed to arise *de novo*. Taken together, our data suggest that approximately 9.7% (the proportion of *de novo* mutations detected from WES that are high-confidence PZMs in Group C)  $\times$  0.84 (the average fraction of genuine *de novo* mutations in Group C)  $\times$  0.92 (the average fraction of genuine PZMs) = 7.5% of all detected *de novo* mutations are likely to be true PZMs detectable by WES, though the recovery of PZMs would be expected to be higher if the exomes had been sequenced at higher coverage.

It is possible that some potential PZMs might be falsely called as a result of copy number variants spanning across the region. As such, we performed TaqMan copy number assays on 36 PZMs in Group C to evaluate the rate of PZMs co-occurring with copy number variants,

but did not detect any (Supplementary Table 5), suggesting that the rate at which copy number variants might overlap with PZMs is likely to be less than 3%.

### PZMs were frequently missed with previous pipelines

Despite the lower overall rate of called *de novo* mutations using our approach compared to previous studies, we found that most PZMs in Group B had not been previously identified (617 out of 1,113 PZMs or 55.4%, Fig. 1D), and an even higher proportion of PZMs in Group C was not previously reported (390 out of 468 PZMs or 83.3%). This suggests that the previous pipelines were more likely to detect gDNMs found only in Group A, and confirms that our approach detects with high specificity many PZMs not previously identified, presumably because these PZMs might have been marked as variants with lower quality and were more likely to be flagged as falsely called variants, despite being readily confirmed by complementary technologies. Our data indicate that over 84.8% of the high-confidence PZMs in Group C were confirmed to be bona fide PZMs through the resequencing experiments, and that 83.3% of the high-confidence PZMs were not previously reported.

### PZMs differ from gDNMs and cancer somatic mutations

Analysis of the mutational properties of PZMs reveal that they show several features that differ from gDNMs. PZMs are enriched on the anti-sense strand (relative to transcription) compared to gDNMs (OR = 1.30, 95% CI = [1.07, 1.58] for Group C, Supplementary Table 6). Anti-sense-strand bias typically reflects the inherent bias of transcription-coupled nucleotide excision repair, which has a higher fidelity on the sense strand. This results in a higher accumulation of mutations on the anti-sense strand<sup>11</sup>, and it is likely that PZMs arise at least in part from this mechanism, similar to previous reports for somatic mosaic mutations in cancers<sup>12</sup>.

The most common types of mutations among gDNMs and PZMs are C-T and G-A mutations. It has been reported that there is a strong preference for mutations from A to C or T to G in the nucleosome core<sup>13</sup>, and we observed a similar enrichment of A-C and T-G mutations in PZMs compared to gDNMs (OR = 2.23, 95% CI = [1.64, 2.99] for Group C, Supplementary Table 7). In particular, we found that the enrichment of A-C mutations was predominantly on the sense strand, whereas the enrichment of T-G mutations was predominantly on the anti-sense strand (Supplementary Table 8). This is a distinct mutational profile from the ones reported for somatic mosaic mutations in cancers<sup>12</sup>, but is suggestive that the enrichment of such mutations in the nucleosome core might affect chromatin remodeling, a process that has been previously found to be perturbed in ASD<sup>14</sup>.

Somatic mutations discovered in cancers have also been reported to be associated with late DNA replication<sup>12</sup>. We correlated PZMs against DNA replication timing during S phase<sup>15</sup> and compared these against the gDNMs found only in Group A (Supplementary Table 9). We observed a similar trend for the PZMs with late replication timing (OR = 1.36, 95% CI = [0.83, 2.14] for Group C), but not with early replication timing (OR = 0.88, 95% CI = [0.72, 1.07] for Group C). However, the association of these PZMs with late replication timing was substantially less than that reported in cancers<sup>16</sup> and was not statistically significant.

Together, these results highlight some unique features of the PZMs. Our data suggest that the mechanisms generating PZMs and their mutational profile are distinct from those of gDNMs. Also, while PZMs detected in blood and somatic mosaic mutations in cancers accumulate preferentially on the anti-sense strand, they differ in the preference for nucleotide base substitutions.

It has been previously reported that germline *de novo* mutations are enriched on the paternal haplotype, and similarly, we observed a 1.69-fold excess of mutations in Group A on the paternal haplotype (1,321 paternal versus 781 maternal, binomial  $P=1.50\times 10^{-32}$ , Supplementary Table 10). In contrast the high-confidence mosaic mutations in Group C did not show any significant excess of mutations on the paternal compared to maternal haplotypes (90 paternal versus 78 maternal, 1.15-fold, binomial  $P=0.2$ ). This confirms that the mutations detected in Group C are likely to be enriched for true PZMs compared to the larger set of Group A mutations.

### **An excess of deleterious PZMs is found in brain-expressed critical exons in ASD probands**

We next investigated whether PZMs might contribute to ASD risk. We first analyzed all *de novo* LoF mutations in Group A, and found the expected excess in probands compared to unaffected siblings, similar to previous reports<sup>4,5</sup>. However, the LoF PZMs from Groups B and C did not show an excess in probands versus siblings (Fig. 2A, Supplementary Table 11). When comparing missense PZMs predicted to be deleterious using three *in-silico* tools (PolyPhen2<sup>17</sup>, SIFT<sup>18</sup> and CADD<sup>19</sup>), we found more *de novo* missense mutations predicted to be deleterious in Groups A and B in probands compared to siblings, but no enrichment for PZMs in Group C (hypergeometric  $P = 0.024$  for Group A,  $P = 0.041$  for Group B, and  $P = 0.32$  for Group C, Supplementary Table 12).

We wondered whether PZMs might contribute to ASD risk by selectively affecting genes expressed in the brain that are subjected to strong purifying selection. It has been previously shown that analysis of “critical exons” – i.e., those that are depleted for deleterious mutations in normal individuals - permits higher sensitivity in detecting differences in germline *de novo* mutations and shows an excess of deleterious PZMs in probands versus unaffected siblings in critical exons expressed in the brain<sup>20</sup>. In line with previous evidence, we observed an enrichment of LoF and missense mutations from Groups A and B found in critical exons in probands versus unaffected siblings (Fig. 2B). Importantly, we also observed an enrichment of high-confidence LoF and missense PZMs from Group C in the probands compared to siblings, further supporting the association of some of these PZMs with ASD.

Mutations in Group A that fall within critical exons are enriched in probands compared to their unaffected siblings in genes expressed across all developmental epochs - early ( < 16 pcw) and late prenatal brains (>16pcw), early childhood (<15 years) and adulthood ( > 15 years). Mutations in Groups B and C that fall within critical exons are enriched in probands for genes expressed in prenatal and early childhood brains, but not adult brains (Fig. 2B), suggesting a particular enrichment for these genes in processes that occur prenatally, including neurogenesis, neuronal migration, dendritogenesis and synaptogenesis. Assessment of PZMs in Group C that fall in critical exons across 16 brain regions during

prenatal development pinpointed the amygdala as the top brain region where PZMs in critical exons are enriched in probands compared to unaffected siblings (Wilcoxon rank sum  $P=5.4\times 10^{-3}$ , Fig. 3, Table 2). Our data suggest that further analyses of PZMs in ASD may begin to unveil brain regions important for the pathophysiology of the disorder.

### **An excess of recurrent PZMs in genes found in probands implicate these genes in ASD**

In probands, 27/735 genes (3.7%) showed recurrent non-synonymous PZMs, versus 2/322 genes (0.62%) with recurrent non-synonymous PZMs in siblings, representing a 6.1-fold excess of genes with recurrent non-synonymous PZMs in the probands (95% CI = [1.52,53.2], Fisher's Exact Test  $P=0.0035$ , permutation  $P = 0.0037$ ). This strongly suggests that some of these genes with recurrent non-synonymous PZMs are relevant for ASD risk.

Given our finding that some genes with recurrent non-synonymous PZMs are likely to confer risk for ASD, we focused on these genes containing recurrent non-synonymous PZMs. We obtained a background set of 84,448 variants that are privately inherited (i.e., variants that are not found in our controls, consisting of parents and siblings, as well as in control databases such as the Exome Variant Server, but were inherited from a parent in an affected or unaffected offspring; see Methods and Supplementary Table 13). Amongst these, we selected a subset with an AAF of 80% or less from the expected modal AAF to obtain a background rate of PZMs in each gene. In addition, we filtered our genes in regions with segmental duplications as described previously<sup>10</sup>, allowing us to exclude genes with falsely called PZMs due to segmental duplications or common copy number variations.

We found 27 genes with recurrent non-synonymous PZMs in the probands, and amongst them, 2 genes (*KLF16* and *MSANTD2*) harbored more PZMs than expected genome-wide based on their background rates (hypergeometric  $P<0.05/18,782$  or  $2.7\times 10^{-6}$ , Table 3). Among the 27 genes, previous studies have reported an excess of germline *de novo* mutations in *SCN2A* found in ASD probands<sup>4,5</sup>, and *de novo* mutations in *HNRNPU* have been associated with epileptic encephalopathies<sup>21</sup>. Our approach detects genes with more recurrent, non-synonymous PZMs than expected from the number of falsely called mutations. There are several reasons why this might occur - for instance, some genes might be less likely to be repaired and thus may tend to accumulate PZMs. Nonetheless, multiple PZMs within well documented neurodevelopmental disease genes like *SCN2A* and *HNRNPU* provide strong evidence that at least some of the post-zygotic mosaic mutations can predispose to ASD.

Among the top genes with recurrent non-synonymous PZMs in probands, 8/10 were expressed in brain (Supplementary Table 14), whereas 2 of the bottom 10 genes with recurrent non-synonymous PZMs in probands showed brain expression. Although there are 2 genes with recurrent non-synonymous PZMs in unaffected siblings, neither of these genes was genome-wide significant (Supplementary Table 15). Germline *de novo* mutations in ASD probands have been reported to be found in genes that are more intolerant to mutation, defined by lower residual variation intolerance scores (RVIS)<sup>22</sup>. We found that genes with recurrent non-synonymous PZMs in probands that scored highest, i.e. had the lowest hypergeometric P-values, showed low RVIS scores, that is, are more intolerant to human



variation (Supplementary Fig. 1). These data all further support a role for some of these PZMs in ASD risk.

It has been repeatedly reported that genes implicated in ASD based on *de novo* mutations are enriched for targets of the Fragile X Mental Retardation Protein (FMRP)<sup>5</sup>. We replicated this observation for *de novo* mutations in Group A (OR = 2.72 [2.35, 3.13],  $P < 1 \times 10^{-10}$ ). We also found a significant enrichment for PZMs in Groups B and C for FMRP target genes (OR = 2.65 [2.04, 3.41],  $P < 1 \times 10^{-10}$ , and OR = 2.06 [1.30, 3.12],  $P = 7.7 \times 10^{-4}$  respectively).

### PZMs in *SMARCA4* down-regulates *GRIN2B*

One of the genes with recurrent non-synonymous PZMs is *SMARCA4*, which encodes BRG1, a critical component of the SWI/SNF chromatin-remodeling complex that regulates gene expression<sup>23</sup>. Germline and somatic LoF mutations in this gene have been implicated in a variety of cancers, including rhabdoid tumors and small cell carcinoma of the ovary of hypercalcemic type<sup>23</sup> (Fig. 4C). On the other hand, germline heterozygous missense mutations in *SMARCA4* have been associated with Coffin-Siris syndrome (OMIM #135900), characterized by intellectual disability. The absence of LoF mutations in *SMARCA4* in Coffin-Siris syndrome suggests that the missense mutations act as gain-of-function or activating mutations, unlike the germline inactivating mutations in cancers<sup>24</sup>.

We detected and confirmed the three missense mutations in *SMARCA4* in the three probands with ASD (p.P143A with AAF 21%, p.I184T with AAF 33%, p.P109L with AAF 36%, Fig. 4A), all predicted to be deleterious using PolyPhen2 and SIFT<sup>17,18</sup>. The p.P143A mutation had a CADD score of 19.81, while the p.I184T and p.P109L mutations had CADD scores of 20 (26.4 and 34 respectively). The p.P109L mutation was previously reported as a somatic mutation in a lung carcinoma sample from the COSMIC database (COSM710132)<sup>25</sup>. CloneSeq on blood-derived DNA for these three individuals with the *SMARCA4* mutations confirmed two of the mutations as likely PZMs (p.P143A: 45 alternate out of 164 total colonies, binomial  $P = 4.9 \times 10^{-9}$ , and p.I184T: 39 alternate out of 118 total colonies, binomial  $P = 1.5 \times 10^{-4}$ ), while the p.P109L mutation is likely germline (p.P109L: 83 alternate out of 164 total colonies, binomial  $P = 0.59$ ).

All three probands had IQs higher than 70 and were confirmed not to show the typical features of Coffin-Siris syndrome. Whereas most *SMARCA4* mutations reported in cancers, such as medulloblastoma, fall within the helicase domains of the protein<sup>26</sup>, the PZMs in *SMARCA4* in ASD probands fell in the N-terminal domain, in a region (between amino acids 1 and 282) that binds CREST<sup>27</sup>, encoded by the *Synovial Sarcoma Translocation Gene On Chromosome 18-Like 1 (SS18L1)* gene (Fig. 4B). The BRG1-CREST complex regulates the NR2B subunit of the ionotropic, N-methyl D-aspartate glutamate receptor<sup>27</sup>, encoded by the ASD risk gene *GRIN2B*<sup>4,5</sup>.

Therefore, we hypothesized that the PZMs in *SMARCA4* might influence the BRG1-CREST interaction and thus the expression of the downstream target *GRIN2B*. To test the hypothesis, we overexpressed wild-type (WT), p.I184T or p.P143A *SMARCA4* in mouse neuroblastoma (N2A) cells and measured the expression of *GRIN2B* by quantitative PCR.

We found that overexpression of either *SMARCA4* mutant led to significantly lower expression of *GRIN2B* compared to wildtype *SMARCA4* (Fig. 4C).

## Discussion

Our systematic analysis of WES from over 5,800 trios found that 7.5% of *de novo* mutations are PZMs, despite the limited sensitivity of WES to detect PZMs due to the relatively low coverage. We established a pipeline for detecting and analyzing PZMs, using 3 independent resequencing technologies, and showed that there is high specificity in our PZM detection. In particular, 84.8-93.3% of the high-confidence Group C PZMs are bona fide PZMs. We also discovered that ASD probands harbor more deleterious PZMs compared to their unaffected siblings in brain-expressed critical exons, supporting a role for some of these PZMs in ASD risk. Our estimate of 7.5% of *de novo* mutations being PZMs is similar to the 6.5% rate reported in an earlier cohort of 50 trios with intellectual disability<sup>28</sup>, as well as a recently reported estimate of 5.4% in 2,388 families with ASD<sup>29</sup>. Furthermore, the size of our dataset has allowed us to explore and confirm the role of PZMs in conferring risk to ASD, analyze the mutational characteristics of PZMs, and begin to use them to study the spatio-temporal distribution of PZMs in ASD. Our analysis also revealed striking enrichment of PZMs within genes that are clinically relevant to ASD, including the bona fide ASD risk gene *SCN2A*. The identification of recurrent non-synonymous PZMs in a small set of genes in ASD probands also provides strong evidence for the clinical importance of PZMs.

The finding that LoF and missense PZMs in critical exons in ASD probands showed enrichment in amygdala expression is intriguing since the amygdala plays key roles in emotional and social responses<sup>30</sup>, such as conditioned fear. Complete bilateral damage in the amygdala in humans results in impaired social judgement<sup>31</sup>, reaffirming the importance of the amygdala in regulating social conditioning and learning. An “amygdala theory” of autism<sup>32</sup> has been supported by recent work that found impaired neuronal responses in the amygdala in individuals with ASD<sup>33</sup>. Sexual dimorphism has also been observed in response to testosterone in the amygdala<sup>34</sup>, which has been proposed to potentially account for some of the gender bias observed in ASD.

We have also identified two PZMs in *SMARCA4*, a gene that encodes a major chromatin factor implicated in cancer and Coffin-Siris syndrome. Both PZMs in *SMARCA4* found in the ASD probands fall within the same N-terminal, CREST-binding domain, forming a complex that regulates the activity-dependent expression of key genes implicated in neuronal plasticity<sup>27</sup>. We discovered that overexpressing *SMARCA4* mutants (with p.I184T and p.P143A) reduces the expression of *GRIN2B*, which encodes a key subunit of the NMDA glutamate receptor that has been previously implicated as an ASD risk gene based on *de novo* LoFs<sup>4,5</sup>. This suggests that the PZMs in *SMARCA4* might impair the function of glutamatergic synapses<sup>35</sup>.

It has been reported that *de novo* CNVs and DNMs associated with ASD are more common in individuals with low non-verbal IQ scores<sup>5</sup>. To test the association of IQ with PZM carriers, we analyzed the 7 probands with recurrent PZMs in 9 of the genes (Fig. 4A) that

had IQ scores available. Two of the 7 probands with PZMs (or 28.6%) had non-verbal IQs of at least 100, compared to two out of 65 probands (or 3.1%) with recurrent *de novo* LoF mutations having non-verbal IQs of at least 100, indicating a 9.3-fold excess of probands with higher non-verbal IQs harboring PZMs (hypergeometric test  $P=0.01$ ). This preliminary observation would need replication in a larger number of individuals in the future to test the hypothesis that individuals harboring PZMs might be less severely affected than individuals harboring gDNMs in terms of cognitive abilities such as IQ, and if PZMs may be overrepresented in a subset of individuals with higher functioning forms of ASD.

Although the number of probands with IQ data is small, our data suggest that recurrent PZMs are found in individuals with higher IQs than previously reported gDNMs associated with ASD. This opens the intriguing possibility that some individuals with higher functioning forms of ASD might harbor PZMs that might distribute to and affect some but not all regions of the brain, such as the amygdala. This is also consistent with previous observations that high-functioning individuals such as unaffected parents might harbor low levels of parental mosaicism at low AAFs and can transmit these mosaic risk alleles to their affected offspring, which will present as germline mutations in the offspring<sup>36</sup>. A previous targeted resequencing experiment discovered a mosaic (AAF ~10%) nonsense mutation in the ASD risk gene *ADNP* in an unaffected parent, providing further anecdotal evidence for this hypothesis<sup>37</sup>. It is also plausible that some PZMs could create mosaic clinical phenotypes where presence of the same mutant allele in the germline would be lethal, such as the *AKT1* E17K mutation that causes Proteus syndrome<sup>38</sup>.

One limitation of our work is that we have not analyzed the potential role of post-zygotic copy number variants (CNV) in ASD. Given the strong association of *de novo* copy number variants with ASD<sup>2,39,40</sup>, it is possible that there might be mosaic CNV that are involved in ASD, and like the PZMs, mosaic CNV might be under-detected in previous large-scale genomics studies looking at primarily germline copy number variants in ASD. Another area worth pursuing in the future is the role of parental mosaicism in ASD. Such mutations, if present at low AAFs such as the *ADNP* example, might result in the parents appearing to be clinically unaffected, but can lead to an increased recurrent risk for disease in their offspring. It will be interesting to survey a large number of unaffected parents (or other control individuals) to understand the rates of mosaicism, and the distribution of AAFs in disease-associated genes, that do not result in a clinical presentation.

Multiple lines of evidence suggest that ASD-associated PZMs detectable in blood samples arose during early development, and are enriched in genes expressed in prenatal but not postnatal post-mortem brains. Many of the PZMs associated with ASD discovered in blood have relatively high AAFs and are thus likely to have arisen relatively early in development. Our previous studies have shown that functionally neutral PZMs with >5% AAF are likely to be found in multiple tissues<sup>8</sup>, suggesting that many of the PZMs discovered in blood are likely to be PZMs in brain tissue as well. Given that 83.3% of the high-confidence PZMs were missed using previous algorithms, it will be important in the future to perform a detailed reanalysis, as well as additional spatio-temporal analyses on PZMs in other neurodevelopmental and psychiatric disorders such as intellectual disability, epilepsy and schizophrenia, to understand the role and contribution of PZMs in these disorders.

## Online Methods

### Standard protocol approval and patient consent

Research performed on samples and data of human origin was conducted according to protocols approved by the institutional review boards of Boston Children's Hospital and Beth Israel Deaconess Medical Center.

### Data processing and annotation

The Autism Sequencing Consortium (ASC) has performed joint calling of the variants in the 5,947 trios from the ASC and the Simons Simplex Collection (SSC) whose exome sequences have been previously published<sup>4,5</sup>. The variants were called using two versions of the GATK<sup>41</sup> (the Unified Genotyper and the Haplotype Caller), and annotated using SnpEff versions 2.0.5 and 3.5<sup>42</sup>. To remove exomes with inheritance errors, as well as potential artifactual mosaic mutations induced by cell passaging, we removed outlier exomes that had more than 2 PZMs or more than 5 *de novo* mutations from downstream analyses.

### PZM detection pipeline applied on the ASC and SSC datasets

We first performed joint-calling of the raw files from the previously published and new exomes, in order to obtain standardized datasets for our analyses. Next, we developed a stringent pipeline to call autosomal *de novo* point mutations from our jointly-called exomes, i.e. mutations that are strictly present in the probands or siblings but are not found in both parents. We refer to all *de novo* mutations as Group A, whereas *de novo* point mutations with AAF equal to or less than 80% of the modal AAF for each cohort are defined as candidate PZMs called "Group B". Mutations in Group B where the deviation from the modal AAF was statistically significant (binomial  $P < 1 \times 10^{-4}$ ) formed "Group C", the group most likely to be PZMs. The AAF was calculated using: number of alternate reads/(total number of reference + alternate reads).

For our initial analyses, we included all variants that passed a set of quality thresholds (genotype quality, GQ  $\geq 20$  and alternate read depth  $\geq 7$ ). All *de novo* variants that were observed only once in a proband and were not observed in 6,500 control individuals from the Exome Variant Server (<http://evs.gs.washington.edu/EVS/>) were included in Group A. In addition, to account for population-specific rare variation, we considered only *de novo* variants that were not observed in unaffected parents and siblings within each study. Given that there might be differences in capture and sequencing approaches across the various cohorts that can result in an over-calling of mosaic mutations, we defined PZMs as variants that deviated from the modal AAF (calculated from all *de novo* variants in Group A) for each cohort, instead of assuming that the modal AAF is 50%. In addition, to reduce false positives as a result of inaccurate realignment, we filtered away PZMs that were within 20bp of an inherited variant. For the final genes with recurrent non-synonymous PZMs, we lowered the quality thresholds to alternate DP  $\geq 3$  in order to screen for additional PZMs that might have been missed, and discovered only an additional non-synonymous PZM in *SMARCA4* (I184T with alternate DP = 4).

## Resequencing of PZMs

For both the ASC and SSC sequencing projects, DNA derived from mostly blood were used for exome sequencing. We resequenced the PZMs using DNA derived from mostly blood and some lymphoblastoid cells and saliva (from the ASC) or blood and lymphoblastoid cells (from the SSC). For our initial evaluation, we selected 50 *de novo* mutations where DNA samples were available (5 from Group A, 28 from Group B and 17 from Group C), and resequenced the mutations using subcloning and Sanger sequencing of the colonies (CloneSeq), targeted PCR followed by MiSeq and pyrosequencing (EpigenDx). Subcloning was performed using the standard protocol with the TA cloning kit (Life Technologies). For targeted PCR, we amplified the genomic regions around the mutations, performed PCR purification (Qiagen) and sheared the amplicons to  $\approx 400$ bp fragments before library preparation and sequencing using MiSeq (paired-end 151bp).

To obtain an estimate of the rate of *de novo* mutations detected with our approach, we performed Sanger sequencing for 82 of the PZMs discovered (39 from Group B and 43 from Group C), using samples obtained from the trios and additional family members if available, to confirm the presence of the mutations, as well as the absence of the mutations in the family members, i.e. to confirm the *de novo* status of the mutations. Given that there is a limitation on detecting low AAFs from Sanger sequencing, we selected variants with AAF  $\geq 10\%$  for the Sanger experiments, and confirmed 73/82 (89%) as *de novo*. In particular, 37/39 (94.9%) of the PZMs from Group B were confirmed to arise *de novo*, and 36/43 (83.7%) of the PZMs from Group C were confirmed to arise *de novo*. In addition, we performed targeted PCR with MiSeq for 327 *de novo* mutations where parental DNA was available, and found that 148/176 (84.1%) of the PZMs from Group C were confirmed to arise *de novo*, 0/18 (0%) of the PZMs from Group B were confirmed to arise *de novo*, and 131/133 (98.5%) of the gDNMs from Group A were confirmed to arise *de novo*.

## Quantitative PCR for assaying copy number variants

For 36 PZMs in Group C where there are copy number variants in the Database of Genomic Variants (<http://dgv.tcag.ca/dgv/app/home>) that are within 2kb of the PZMs, we selected pre-designed primers from ThermoFisher that assay the copy number variants. The DNA samples used for these quantitative PCR assays were extracted from whole blood samples from the Simons Simplex Collection, and the quantitative PCR assays were performed by the Biopolymers core facility at Harvard Medical School. The reference assay used was *AGO1*.

## DNA replication timing analyses

We used data that was previously published<sup>15</sup>, and mapped the genes from the human genome (hg19 assembly) to the regions with the reported replication timing. We defined early replicating genes as genes that fall within regions with replication timing  $Z \geq 1$  and late replicating genes as genes that fall within regions with replication timing  $Z < -1$ .

## Phasing of *de novo* mutations

We ran the ReadBackedPhasing tool in GATK to phase the *de novo* mutations using a 100kb window around the mutation of interest. Out of the 4,846 *de novo* mutations in Group A, we

phased 2,102 of these mutations (43.4%). Of the 1,113 mutations in Group B, we phased 464 of these (41.7%), and of the 468 mutations in Group C, we were able to phase 168 of these (35.9%).

### ***In-silico* prediction for missense mutations**

We used three different tools (PolyPhen2<sup>17</sup>, SIFT<sup>18</sup> and CADD<sup>19</sup>) to obtain *in-silico* predictions for the missense mutations. We defined “deleterious mutations” as all mutations that were predicted by PolyPhen2 to be “probably damaging”, by SIFT to be “damaging”, and had CADD scores of  $\geq 20$ . We further defined “benign mutations” as all mutations that were predicted by PolyPhen2 to be “possibly damaging” or “benign”, by SIFT to be “tolerated”, and had CADD scores of  $<20$ .

### **Critical exon analyses**

We used whole-genome sequencing data from the 1000 Genomes Project<sup>43</sup> to compute the burden of rare missense and loss-of-function mutations for each exon. Furthermore, exon level expression data from RNA sequencing was obtained for 524 brain tissues (prenatal and postnatal postmortem donors) from the BrainSpan project<sup>44</sup>. To classify critical exons, we computed the 75th percentile of brain expression and mutational burden for each exon as described in Uddin *et al*<sup>20</sup>. In short, a critical exon is defined as an exon where expression is high ( $>75$ th percentile) and the accumulation of deleterious mutation is low ( $<75$ th percentile). For each group (A, B and C) of mutations in the probands and siblings, we first computed the fraction of critical exons with non-synonymous and synonymous mutations for each brain tissue sample. Next, we computed the odds ratio for each tissue sample by normalizing the fraction of critical exons detected with the non-synonymous mutations by the fraction of critical exons detected with the synonymous mutations. Each data point corresponds to a ratio for each expression sample that was inferred from the non-synonymous/synonymous mutation counts in critical exons.

### **Inherited variant analyses**

To obtain a background rate for comparing the non-synonymous post-zygotic mutations detected from the exomes beyond false calls, we obtained all the inherited variants that are  $\geq 1\%$  in the population, and selected all variants with AAFs  $\geq 80\%$  of the modal AAF calculated from the *de novo* mutations. We used these inherited variants that deviated from the expected modal AAF for modeling the background rates of obtaining PZMs in each gene, in order to account for technical biases resulting from amplification, exome capture or sequencing. To evaluate the significance of observing recurrent PZMs in each gene beyond expected false calls, we calculated the hypergeometric test P-value by comparing the observed number of PZMs for each gene with the expected background gene-specific mutation rates (Supplementary Table 13). The genome-wide threshold was calculated as  $P < 0.05/18,782 = 2.7 \times 10^{-6}$  as there are 18,782 annotated genes in the data.

### **Spatial and temporal analyses**

To evaluate the distributions of mutations found in genes that are expressed in post-mortem brains (prenatal and postnatal), as well as in specific regions of the brain, we downloaded the

RNA sequencing data from the BrainSpan project<sup>44</sup> (<http://www.brainspan.org>). For the spatial analyses, we focused on 16 brain regions (VIC: primary visual cortex; STC: posterior (caudal) superior temporal cortex; IPC: posterior inferior parietal cortex; A1C: primary auditory cortex; S1C: primary somatosensory cortex; M1C: primary motor cortex; DFC: dorsolateral prefrontal cortex; MFC: medial prefrontal cortex; VFC: ventrolateral prefrontal cortex; OFC: orbital frontal cortex; ITC: inferolateral temporal cortex; AMY: amygdaloid complex; CBC: cerebellar cortex; HIP: hippocampus; MD: mediodorsal nucleus of thalamus; and STR: striatum).

### FMRP target dataset

To evaluate the enrichment of FMRP targets, we obtained a list of the transcripts published in Darnell JC *et al.*<sup>45</sup> that were previously used to evaluate the *de novos* in ASD<sup>46</sup> and schizophrenia<sup>47</sup>.

### Residual Variation Intolerance Score (RVIS) analyses

We downloaded the RVIS gene scores based on variants reported in the ExAC database with allele frequencies up to 1% ([http://genic-intolerance.org/data/RVIS\\_Unpublished\\_ExAC\\_May2015.txt](http://genic-intolerance.org/data/RVIS_Unpublished_ExAC_May2015.txt), accessed: October 11<sup>th</sup> 2016).

### Permutations for comparing proband PZMs to sibling PZMs

There are 786 PZMs in Group B found in the probands, resulting in 27/735 genes with recurrent non-synonymous PZMs. Conversely, there are 327 PZMs in Group B found in the unaffected siblings, resulting in 2/322 (0.62%) genes with recurrent non-synonymous PZMs. To evaluate the significance of the excess of recurrent PZMs found in probands compared to recurrent PZMs found in siblings, we randomly sampled 327 PZMs from the 786 PZMs discovered in the probands. 367/100,000 permutations resulted in the proportion of recurrent genes being less than or equal to 2/322.

### Mutations in *SMARCA4*

We compiled a subset of germline and somatic mutations that were reported in cancers<sup>48,49</sup>, as well as Coffin-Siris syndrome<sup>50</sup>.

### Mutagenesis of *SMARCA4* plasmid

We used the human *SMARCA4* transcript variant 3 that was cloned into a pCMV6-AC-GFP backbone (Origene cat no. RG219258). The primers used for the mutagenesis were designed using the Agilent QuikChange design tool, and mutagenesis was performed using the standard protocol with the Agilent QuikChange II XL kit. All mutants were confirmed using Sanger sequencing and plasmids were extracted using the endotoxin-free QIAGEN Plasmid Maxi Kit. We attempted mutagenesis for all 3 *SMARCA4* mutants (c.326C>T or p.P109L, c.427C>G or p.P143A and c.551T>C or p.I184T), but only 2 of the mutagenesis experiments resulted in colonies (c.427C>G and c.551T>C). We repeated the mutagenesis experiments for the c.326C>T mutant using the Q5 Site-Directed Mutagenesis Kit (New England BioLabs), but did not get any colonies either.

The primers used for the p.P143A (c.427C>G) QuikChange mutagenesis experiment are:

Forward: 5' - gaagacatctgggccccgaagacggg -3'

Reverse: 5' - cccgtcttcggggcccagatgtcttc -3'

The primers used for the p.I184T (c.551T>C) QuikChange mutagenesis experiment are:

Forward: 5' - catctttaggccatggtctgagctctgagctg -3'

Reverse: 5' - cagctcagagctcagaccatggcctacaagatg -3'

### Overexpression of *SMARCA4* plasmids in N2A cells

P4 Mouse neuroblastoma (N2A) cells commercially available from ATCC were tested negative for mycoplasma, and were passaged in DMEM with L-Glutamine, 4.5g/L Glucose and Sodium Pyruvate (Thermo Fisher Scientific) with 10% Fetal Bovine Serum (Thermo Fisher Scientific) and 1% Penicillin Streptomycin (Thermo Fisher Scientific). 24µg of wildtype or mutant plasmids were transfected into 90% confluent N2A cells in 10cm tissue culture plates using Lipofectamine 2000 (Life Technologies). The transfections for each plasmid (wildtype and 2 mutants) were performed in triplicates. Selection was performed by adding 1000µg/ml of G418 antibiotic (Life Technologies) 24 hours after transfection to each plate for 10 days, changing fresh antibiotics every 3 days. 3 additional plates of wildtype N2A cells were grown without selection as controls.

### RNA extraction and qPCR

The N2A cells were dissociated using 0.05% Trypsin-EDTA (Life Technologies) and washed with PBS (Life Technologies). RNA extraction was performed using the Ambion PureLink RNA Mini Kit (Life Technologies) and cDNA synthesis was performed using the SuperScript III First-Strand kit (Life Technologies). The KAPA SYBR FAST qPCR master mix was added to 1µg of cDNA and 1µl of each 10µM forward and reverse primers for the qPCR experiments.

The primers used for the mouse *ACTB* qPCR experiment are:

Forward: 5' - GGCTGTATCCCCTCCAATCG -3'

Reverse: 5' - CCAGTTGGTAACAATGCCATGT -3'

The primers used for the mouse *GRIN2B* qPCR experiment are:

Forward: 5' - CAGCAAAGCTCGTTCGCCAAAA -3'

Reverse: 5' - GTCAGTCTCGTTCATGGCTAC -3'

To obtain the log<sub>2</sub> expression levels for *GRIN2B*, we first calculated the  $Ct = Ct_{GRIN2B} - Ct_{ACTB}$  for all the qPCR results obtained from the mutants, wildtypes and controls, and normalized the log<sub>2</sub> expression levels by calculating  $Ct = Ct_{control} - Ct_{(mutant\ or\ wildtype)}$ .



**Code availability**

All analyses were performed using custom Perl and R scripts, which are available on request.

**Data availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request. The codes and scripts have also been uploaded to <https://pgpresearch.med.harvard.edu/mosaic/>

BrainSpan Project: <http://www.brainspan.org>

Exome Variant Server: <http://evs.gs.washington.edu/EVS/>

RVIS: [http://genic-intolerance.org/data/RVIS\\_Unpublished\\_ExAC\\_May2015.txt](http://genic-intolerance.org/data/RVIS_Unpublished_ExAC_May2015.txt)

Database of Genomic Variants: <http://dgv.tcag.ca/dgv/app/home>

**Statistics**

To compare the strand bias among mutations, we calculated the 2-tailed Fisher's Exact Test P-values for the numbers of mutations found on the sense and anti-sense strands in Groups B and C compared to the numbers of mutations in Group A (exact numbers are shown in Supplementary Table 6).

To compare the differences in mutational properties, we calculated the 2-tailed Fisher's Exact Test P-values for the numbers of A>C and T>G mutations in Groups B and C to the numbers of mutations in Group A (exact numbers are shown in Supplementary Table 7).

To compare the strand-specific differences in mutational properties, we calculated the 2-tailed Fisher's Exact Test P-values for the numbers of A>C and T>G mutations found on the sense and anti-sense strands in Groups B and C to the numbers of mutations in Group A (exact numbers are shown in Supplementary Table 8).

To compare the association of PZMs with replication timing, we calculated the 2-tailed Fisher's Exact Test P-values for the numbers of mutations with early or late replication times in Groups B and C compared to the numbers of mutations in Group A (exact numbers are shown in Supplementary Table 9).

To compare the enrichment of mutations on the paternal or maternal haplotypes, we calculated the binomial test P-values for the numbers of mutations in Groups A-C (exact numbers are shown in Supplementary Table 10).

To compare the functional distribution of mutations in probands versus unaffected siblings, we calculated the hypergeometric P-values for the numbers of mutations in Groups A-C for probands and siblings (exact numbers are shown in Supplementary Table 11).

To compare the rates of predicted deleterious missense mutations in probands compared to siblings, we calculated the 1-tailed Fisher's Exact Test P-values for Groups A-C (exact numbers are shown in Supplementary Table 12).

To prioritize the genes with recurrent non-synonymous PZMs found in the probands, we calculated the hypergeometric P-values for each gene (exact numbers are shown in Supplementary Tables 13-14). Similarly, we calculated the hypergeometric P-values for each gene with recurrent non-synonymous PZMs found in the unaffected siblings and the exact numbers are shown in Supplementary Table 15.

No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications<sup>4,5</sup>. Data collection and analysis were not performed blind to the conditions of the experiments.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We are grateful to all the families who participated in the research, including the Simons Foundation Autism Research Initiative (SFARI) Simplex Collection (SSC), the Autism Sequencing Consortium (ASC) and Autism Speaks. We acknowledge the clinicians and organizations that contributed to samples used in this study, including the ASC and SSC principal investigators, the coordinators and staff at the ASC and SSC sites for the recruitment and comprehensive assessment of simplex families, and the ASC, SFARI and NDAR staff for facilitating access to the datasets. We also thank the 3 anonymous reviewers for their critical suggestions, which have helped to improve the work significantly. This work was supported by a grant from the Simons Foundation (178093, C.A.W.), grants from the National Institutes of Health (NIH) R01MH083565, RC2MH089952, U01MH106883 (C.A.W.), as well as grants R01MH097849, U01MH100233, U01MH100209, U01MH100229, U01MH100239 and U01MH111661-01 to the Autism Sequencing Consortium, grants from the Centre for Applied Genomics, the University of Toronto McLaughlin Centre, Genome Canada and Autism Speaks (S.W.S.), SRPBS and Brain/MINDS grants from AMED (I.K., B.A., N.O.), grants from the Spanish Ministry of Economy and Competitiveness (M.P.), Instituto de Salud Carlos III (M.P.), PI10/02989 (M.P.), CIBERSAM (M.P.) and ERA-NET NEURON (M.P., C.M.F.), Network of European Funding for Neuroscience Research (M.P.), and Fundación María José Jove and The Institute of Health Carlos III-Fondo de Investigaciones Sanitarias grant project PI13/01136 (A.C.). We thank A. Hossain and N. Hatem for their help with sample preparation, F. Zhao and C. Stevens for their help with reprocessing the BAM files, as well as M. Daly, S. McCarroll, G. Genovese and J. Hirschhorn for helpful comments and suggestions. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD018522. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported in part through the computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. Additional computing support was provided by the Harvard Medical School's Orchestra High-Performance Computing Group, which is partially supported by NIH grant NCRR 1S10RR028832-01. The NHLBI GO Exome Sequencing Project and its ongoing studies produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). C.A.W. is an Investigator of the Howard Hughes Medical Institute. S.W.S. is the GlaxoSmithKline-Canadian Institutes of Health Research Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. M.U. is a Banting postdoctoral fellow. A.M.D. is supported by the NIGMS (T32GM007753) and NRSA (5T32 GM007226-39). S.D.R. is a Seaver fellow, supported by the Seaver Foundation


## References

1. Gaugler T, et al. Most genetic risk for autism resides with common variation. *Nature genetics*. 2014; 46:881–885. DOI: 10.1038/ng.3039 [PubMed: 25038753]

2. Sanders SJ, et al. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. *Neuron*. 2015; 87:1215–1233. DOI: 10.1016/j.neuron.2015.09.016 [PubMed: 26402605]
3. Pinto D, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *American journal of human genetics*. 2014; 94:677–694. DOI: 10.1016/j.ajhg.2014.03.018 [PubMed: 24768552]
4. De Rubeis S, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature*. 2014; 515:209–215. DOI: 10.1038/nature13772 [PubMed: 25363760]
5. Iossifov I, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature*. 2014; 515:216–221. DOI: 10.1038/nature13908 [PubMed: 25363768]
6. Yu TW, et al. Using whole-exome sequencing to identify inherited causes of autism. *Neuron*. 2013; 77:259–273. DOI: 10.1016/j.neuron.2012.11.002 [PubMed: 23352163]
7. Lim ET, et al. Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders. *Neuron*. 2013; 77:235–242. DOI: 10.1016/j.neuron.2012.12.029 [PubMed: 23352160]
8. Januar SS, et al. Somatic mutations in cerebral cortical malformations. *The New England journal of medicine*. 2014; 371:733–743. DOI: 10.1056/NEJMoa1314432 [PubMed: 25140959]
9. Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. *Science*. 2013; 341:1237758. [PubMed: 23828942]
10. Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *The New England journal of medicine*. 2014; 371:2477–2487. DOI: 10.1056/NEJMoa1409405 [PubMed: 25426838]
11. Pleasance ED, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*. 2010; 463:191–196. DOI: 10.1038/nature08658 [PubMed: 20016485]
12. Polak P, et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. *Nature*. 2015; 518:360–364. DOI: 10.1038/nature14221 [PubMed: 25693567]
13. Prendergast JG, Semple CA. Widespread signatures of recent selection linked to nucleosome positioning in the human lineage. *Genome research*. 2011; 21:1777–1787. DOI: 10.1101/gr.122275.111 [PubMed: 21903742]
14. Cotney J, et al. The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. *Nature communications*. 2015; 6:6404.
15. Koren A, et al. Differential relationship of DNA replication timing to different forms of human mutation and variation. *American journal of human genetics*. 2012; 91:1033–1040. DOI: 10.1016/j.ajhg.2012.10.018 [PubMed: 23176822]
16. Woo YH, Li WH. DNA replication timing and selection shape the landscape of nucleotide variation in cancer genomes. *Nature communications*. 2012; 3:1004.
17. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Current protocols in human genetics / editorial board, Jonathan L. Haines ... [et al.]*. 2013; Chapter 7 Unit7 20.
18. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nature protocols*. 2009; 4:1073–1081. DOI: 10.1038/nprot.2009.86 [PubMed: 19561590]
19. Kircher M, et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nature genetics*. 2014; 46:310–315. DOI: 10.1038/ng.2892 [PubMed: 24487276]
20. Uddin M, et al. Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder. *Nature genetics*. 2014; 46:742–747. DOI: 10.1038/ng.2980 [PubMed: 24859339]
21. Carvill GL, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nature genetics*. 2013; 45:825–830. DOI: 10.1038/ng.2646 [PubMed: 23708187]
22. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. *PLoS genetics*. 2013; 9:e1003709. [PubMed: 23990802]


23. Jelinic P, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. *Nature genetics*. 2014; 46:424–426. DOI: 10.1038/ng.2922 [PubMed: 24658004]
24. Kosho T, Okamoto N. Coffin-Siris Syndrome International, C. Genotype-phenotype correlation of Coffin-Siris syndrome caused by mutations in SMARCB1, SMARCA4, SMARCE1, and ARID1A. *American journal of medical genetics Part C, Seminars in medical genetics*. 2014; 166C: 262–275. DOI: 10.1002/ajmg.c.31407
25. Forbes SA, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic acids research*. 2015; 43:D805–811. DOI: 10.1093/nar/gku1075 [PubMed: 25355519]
26. Pugh TJ, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature*. 2012; 488:106–110. DOI: 10.1038/nature11329 [PubMed: 22820256]
27. Qiu Z, Ghosh A. A calcium-dependent switch in a CREST-BRG1 complex regulates activity-dependent gene expression. *Neuron*. 2008; 60:775–787. DOI: 10.1016/j.neuron.2008.09.040 [PubMed: 19081374]
28. Acuna-Hidalgo R, et al. Post-zygotic Point Mutations Are an Underrecognized Source of De Novo Genomic Variation. *American journal of human genetics*. 2015; 97:67–74. DOI: 10.1016/j.ajhg.2015.05.008 [PubMed: 26054435]
29. Freed D, Pevsner J. The Contribution of Mosaic Variants to Autism Spectrum Disorder. *PLoS genetics*. 2016; 12:e1006245. [PubMed: 27632392]
30. Morris JS, Ohman A, Dolan RJ. Conscious and unconscious emotional learning in the human amygdala. *Nature*. 1998; 393:467–470. DOI: 10.1038/30976 [PubMed: 9624001]
31. Adolphs R, Tranel D, Damasio AR. The human amygdala in social judgment. *Nature*. 1998; 393:470–474. DOI: 10.1038/30982 [PubMed: 9624002]
32. Baron-Cohen S, et al. The amygdala theory of autism. *Neuroscience and biobehavioral reviews*. 2000; 24:355–364. [PubMed: 10781695]
33. Rutishauser U, et al. Single-neuron correlates of atypical face processing in autism. *Neuron*. 2013; 80:887–899. DOI: 10.1016/j.neuron.2013.08.029 [PubMed: 24267649]
34. Xu X, et al. Modular genetic control of sexually dimorphic behaviors. *Cell*. 2012; 148:596–607. DOI: 10.1016/j.cell.2011.12.018 [PubMed: 22304924]
35. Gkogkas CG, et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. *Nature*. 2013; 493:371–377. DOI: 10.1038/nature11628 [PubMed: 23172145]
36. Campbell IM, et al. Parental somatic mosaicism is underrecognized and influences recurrence risk of genomic disorders. *American journal of human genetics*. 2014; 95:173–182. DOI: 10.1016/j.ajhg.2014.07.003 [PubMed: 25087610]
37. O'Roak BJ, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. *Nature communications*. 2014; 5:5595.
38. Lindhurst MJ, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. *The New England journal of medicine*. 2011; 365:611–619. DOI: 10.1056/NEJMoa1104017 [PubMed: 21793738]
39. Weiss LA, et al. Association between microdeletion and microduplication at 16p11.2 and autism. *The New England journal of medicine*. 2008; 358:667–675. DOI: 10.1056/NEJMoa075974 [PubMed: 18184952]
40. Sebat J, et al. Strong association of de novo copy number mutations with autism. *Science*. 2007; 316:445–449. DOI: 10.1126/science.1138659 [PubMed: 17363630]
41. DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature genetics*. 2011; 43:491–498. DOI: 10.1038/ng.806 [PubMed: 21478889]
42. Cingolani P, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly*. 2012; 6:80–92. DOI: 10.4161/fly.19695 [PubMed: 22728672]
43. Genomes Project C, et al. A map of human genome variation from population-scale sequencing. *Nature*. 2010; 467:1061–1073. DOI: 10.1038/nature09534 [PubMed: 20981092]
44. Kang HJ, et al. Spatio-temporal transcriptome of the human brain. *Nature*. 2011; 478:483–489. DOI: 10.1038/nature10523 [PubMed: 22031440]

45. Darnell JC, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell*. 2011; 146:247–261. DOI: 10.1016/j.cell.2011.06.013 [PubMed: 21784246]
46. Iossifov I, et al. De novo gene disruptions in children on the autistic spectrum. *Neuron*. 2012; 74:285–299. DOI: 10.1016/j.neuron.2012.04.009 [PubMed: 22542183]
47. Fromer M, et al. De novo mutations in schizophrenia implicate synaptic networks. *Nature*. 2014; 506:179–184. DOI: 10.1038/nature12929 [PubMed: 24463507]
48. Ramos P, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. *Nature genetics*. 2014; 46:427–429. DOI: 10.1038/ng.2928 [PubMed: 24658001]
49. Le Loarer F, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. *Nature genetics*. 2015; 47:1200–1205. DOI: 10.1038/ng.3399 [PubMed: 26343384]
50. Tsurusaki Y, et al. Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. *Nature genetics*. 2012; 44:376–378. DOI: 10.1038/ng.2219 [PubMed: 22426308]




**Figure 1. *De novo* mutations in ASD show an excess of low alternate allele frequencies, consistent with post-zygotic mosaicism**

(a) There is an excess of variants with low AAFs among the *de novo* mutations, which are likely to be post-zygotic mutations. (b) Rates of mutations in the datasets for all *de novos* in Group A, as well as mosaics in Groups B and C. (c) Correlation of AAFs for PZMs across the AAF spectrum using multiple technologies ( $n=49$  mutations for CloneSeq,  $n=46$  mutations for Pyroseq,  $n=42$  mutations for MiSeq), with higher correlations (Pearson's  $r^2=0.85$  for CloneSeq and MiSeq,  $r^2=0.63$  for CloneSeq and Pyroseq). (d) Percentages of identified *de novo* variants that were identified by previous analyses or novel from Groups A, B and C. The majority of high-confidence PZMs from Group C were not detected by previous calling algorithms.




**Figure 2. Post-zygotic mutations in ASD show excess deleterious mutations in critical exons of early developmental brain expressed genes**

(a) There is no statistically significant global excess of Group C PZMs in the probands (red) compared to their unaffected siblings (blue), hypergeometric  $P=0.32$  for fraction of LoF variants in probands compared to siblings. (b) As expected, there are highly significant excesses in overall gDNMs (Group A) for genes expressed in prenatal and adult brains. For Groups B and C, representing potential and high-confidence PZMs, there is a strong excess of LoF and missense mutations in critical exons that are expressed in EPN (early prenatal) and LPN (late prenatal), 1-tailed Wilcoxon rank sum test  $P < 1 \times 10^{-5}$ , but not ECH (early childhood) or ADU (adult) post-mortem brain samples in the probands, 1-tailed Wilcoxon rank sum test  $P > 1 \times 10^{-5}$ .



**Figure 3. Post-zygotic mutations implicate the prenatal amygdala in ASD**  
 Spatial representation of the regions that are enriched for PZMs in Group C in the probands, and the 1-tailed Wilcoxon rank sum test  $P=5.4 \times 10^{-3}$  for the top brain region (AMY – amygdala).





**Figure 4. Recurrent non-synonymous post-zygotic mosaic mutations implicate novel genes with more mutations than expected false calls**

(a) Sanger sequencing traces for the 3 *SMARCA4* mutations. (b) *SMARCA4* mutations reported in cancers, Coffin-Siris syndrome and ASD. (c) qPCR results for *GRIN2B* after overexpression and selection of wildtype and mutant (p.P143A and p.I184T) human *SMARCA4* in N2A cells, with the values for each replicate experiment ( $N=3$  each for WT, P143A and I184T) in red dots (unpaired t-test  $P=0.0031$  for P143A compared to wildtype and  $P=0.015$  for I184T compared to wildtype).

**Table 1**  
**Validation rates for mutations detected from WES**

Rates at which predicted PZMs from WES were also found to be *de novo* with unequal AAFs using three different technologies.

<b>Phase 1: Resequencing of initial 50 mutations to evaluate if AAFs 40%</b>			
	<b>High-confidence PZMs from Group C</b>	<b>Less stringent PZMs found in Group B but not Group C</b>	<b>Potential germline <i>de novos</i> found in Group A but not Group B</b>
CloneSeq	14 / 16 (87.5%)	7 / 28 (25%)	1 / 5 (20%)
Pyrosequencing	13 / 15 (87%)	10 / 26 (38%)	2 / 5 (40%)
Targeted PCR + MiSeq	14 / 15 (93.3%)	6 / 24 (25%)	0 / 3 (0%)
<b>Phase 2: Resequencing of 181 mutations to evaluate if AAFs 40%</b>			
Pyrosequencing	28 / 33 (84.8%)	20 / 78 (25.6%)	-
Targeted PCR + MiSeq	52 / 61 (85.2%)	10 / 73 (13.7%)	1 / 12 (8.3%)
<b>Phase 3: Resequencing of 325 mutations to evaluate if AAFs 40%</b>			
Targeted PCR + MiSeq	159 / 164 (97.0%)	3 / 17 (17.6%)	4 / 144 (2.8%)

**Table 2**  
**Regions that are enriched for PZMs in Group C in the probands compared to their unaffected siblings**

The P-values reported are calculated using a 2-tailed Wilcoxon rank sum test.

<b>Brain Region</b>	<b>Group C Wilcoxon Test P</b>
Amygdala (AMY)	$5.4 \times 10^{-3}$
Striatum (STR)	0.065
Cerebellar cortex (CBC)	0.093
Hippocampus (HIP)	0.10
Posteroinferior parietal cortex (IPC)	0.27
Primary visual cortex (VIC)	0.43
Primary auditory cortex (AIC)	0.48
Primary motor cortex (MIC)	0.49
Mediodorsal nucleus of thalamus (MD)	0.59
Posterior superior temporal cortex (STC)	0.69
Medial prefrontal cortex (MFC)	0.71
Ventrolateral prefrontal cortex (VFC)	0.71
Inferior temporal cortex (ITC)	0.80
Dorsolateral prefrontal cortex (DFC)	0.96
Orbital prefrontal cortex (OFC)	0.96
Primary somatosensory cortex (SIC)	1

**Table 3**  
**List of top 10 genes with recurrent non-synonymous PZMs from Group B**

Genes with recurrent non-synonymous PZMs from Group B found in the probands (observed), with the observed number of mosaics that are inherited (expected), as well as the hypergeometric test P-value. The genes that are expressed in the brain are highlighted in red.

	Expected	Observed	Hypergeometric P
KLF16	0/84448	2/571	$<1 \times 10^{-6}$
MSANTD2	1/84448	2/571	$<1 \times 10^{-6}$
POLA2	2/84448	2/571	$4.6 \times 10^{-5}$
SMARCA4	11/84448	3/572	$4.9 \times 10^{-5}$
AZGP1	4/84448	2/571	$2.7 \times 10^{-4}$
CNGB3	5/84448	2/571	$4.5 \times 10^{-4}$
HNRNPU	5/84448	2/571	$4.5 \times 10^{-4}$
SCN2A	5/84448	2/571	$4.5 \times 10^{-4}$
EPPK1	58/84448	4/571	$6.6 \times 10^{-4}$
CARD11	7/84448	2/571	$9.4 \times 10^{-4}$